Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 5/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27540830 | 0.83 | NPC1 (0.73) | NPC1RAB9AGAACYP3A4ALDH1A1 | |
| SCHEMBL6877183 | 0.83 | NPC1 (0.73) | NPC1RAB9AGAACYP3A4ALDH1A1 | |
| SCHEMBL5871961 | 0.83 | NPC1 (0.73) | NPC1RAB9AGAACYP3A4ALDH1A1 | |
| SCHEMBL28324288 | 0.80 | TSHR (0.59) | NPC1RAB9AFAAHGAAUSP2 | |
| SCHEMBL20705956 | 0.80 | POLB (0.50) | FAAHGAAUSP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL28379301 | 0.80 | POLB (0.50) | FAAHGAAUSP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL28680133 | 0.79 | FAAH (0.51) | NPC1RAB9AFAAHGAAUSP2 | |
| SCHEMBL28662483 | 0.78 | FAAH (0.50) | NPC1RAB9AFAAHGAAUSP2 | |
| SCHEMBL28671891 | 0.78 | FAAH (0.50) | NPC1RAB9AFAAHGAAUSP2 | |
| SCHEMBL28666524 | 0.78 | FAAH (0.49) | NPC1RAB9AFAAHGAAUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132500-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA INC (US) | 2024-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132500-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | TYMP, TYMS, P2RX7 | NPC1 1706/4885RAB9A 2028/4885FAAH 3045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.